Xinglian Pharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as "Xinglian Pharmaceutical") was incorporated in July 2018 with a registered capital of RMB 200 million. It is an innovative antibody drug R&D and manufacturing enterprise based in China and oriented toward the globe, focusing on the research, development, manufacturing and commercialization of therapies for immune diseases, mainly developing monoclonal antibody-based biologics, and is committed to becoming a biopharmaceutical company that develops innovative drugs to fill unmet medical needs. Xinglian Pharmaceutical is a major science and technology project of Suzhou Industrial Park. It was wholly established by China Antibody Pharmaceutical Co., Ltd. (hereinafter referred to as "China Antibody", stock code: 03681HK), a company listed on the Main Board of the Hong Kong Stock Exchange, and serves as its headquarters and industrialization base for R&D, production, sales and operations in mainland China.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows